Recombinant DNA-based products are slow to reach the marketplace because of the significant expenses needed to develop these products along with the lengthy time it takes to develops these treatments and medicines. Also, even as recent as 2005, several large pharmaceutical companies resisted the development of their own recombinant DNA research facilities.